A proud moment for our team. KCSA has been named one of @RaganComms 2026 Top Places to Work in Communications for the third year in a row—thanks to the people who make the work meaningful every day. Congrats to all of this year’s honorees 👏

Congratulations to our client Childfree Trust, named one of TIME's Best Inventions of 2026. Childfree Trust is the first nationwide fiduciary estate planning and next-of-kin solution for childfree and permanently childless adults. Read TIME's write-up: time.com/collection/best-inv…

The @MaximGrp Growth Summit 2026 is underway, and KCSA Strategic Communications is proud to be a Gold Sponsor. Our team is on the ground in New York City, connecting with public company executives, investors and capital markets professionals.

@kcsastrategic is a Gold Sponsor of the @MaximGrp Growth Summit 2026 in New York. KCSA will be there October 12–14 alongside the companies, investors and capital markets professionals taking part in this year’s Summit. We’re glad to be part of it.

Ibogaine started as a last resort. Now it’s attracting a different kind of client. @kcsastrategic client @BeondUs Inc. is featured in the New York Post. nypost.com/2026/10/02/health…

@kcsastrategic's CHRO Katie Roland joined the @HRGrapevine Podcast to unpack the communication gap between managers and new professionals, from punctuation panic to phone call anxiety. Listen: hrgrapevine.com/us/content/a… #Leadership #WorkplaceCulture

@kcsastrategic client, @newcelXltd (Nasdaq: NCEL), is advancing IND-enabling activities for NCEL-101 following constructive FDA Pre-IND feedback. Read the full announcement here: globenewswire.com/news-relea… #KCSA #NewCelX #Type1Diabetes #CellTherapy #Biotech

@kcsastrategic client @ibs_inc_ (@Nasdaq: $INBS) hosts a virtual fireside chat Sept 24 at 4:30pm ET on its FDA 510(k) submission, clinical data, and commercial progress outside the US, with CEO @simeonidis68 and VP Peter Passaris. Register: us02web.zoom.us/webinar/regi…

Today, @kcsastrategic celebrates our 57th anniversary. We are grateful to our clients for their trust, to our employees for their dedication, and to the founders who established the firm 57 years ago. We look forward to continuing the work in the years ahead.

On Sept 23, @kcsastrategic client IMUNON, Inc. (@Nasdaq: $IMNN) hosts a live R&D Day on IMNN-001, its IL-12 immunotherapy for advanced ovarian cancer, with leadership, trial investigators, and an OVATION 1 patient conversation. Register here: edge.media-server.com/mmc/p/…

@kcsastrategic client Intelligent Bio Solutions (@Nasdaq: $INBS) submitted a 510(k) to the FDA for its fingerprint-based drug screening system for codeine detection. Study results: 98%+ accuracy, 94%+ sensitivity, 100% specificity. ibs.inc/2026/09/09/inbs-subm… #MedTech #FDA

Modular Medical, Inc. (@Nasdaq: $MODD) has received FDA clearance for software enhancements to its Pivot™ tubeless insulin patch pump, arriving ahead of its planned fourth quarter commercial launch. Learn more: ir.modular-medical.com/press…

@kcsastrategic's IR Team is preparing for the @HCWCO, LLC 28th Annual Global Investment Conference at the Lotte New York Palace Hotel, September 14–16. Send us a DM to set up time. We'll see you in New York!

ABC affiliate in Nebraska recently highlighted how our client RenovoRx (@Nasdaq: $RNXT) is changing what chemotherapy feels like for pancreatic cancer patients. Read the full story by Danielle DaSilva on KLKN-TV: klkntv.com/a-new-way-to-deli…

Ticketplus (@NYSE American: $TP) reported its results for the first half of 2026, its first release as a newly public company, and the results speak for themselves. Read the full release: businesswire.com/news/home/2…

Our clients have 4 sessions up for SXSW 2027 voting! Click each link + heart to support: Triton Digital: participate.sxsw.com/flow/sx… participate.sxsw.com/flow/sx… Future Today: participate.sxsw.com/flow/sx… IAB: participate.sxsw.com/flow/sx… Vote by Aug. 23!

@kcsastrategic congratulates our client Ticketplus Ltd. on the pricing of its $15 million initial public offering. Ticketplus priced 1,875,000 ordinary shares at $8.00 per share, and began trading today on the @NYSE American under the ticker symbol $TP. globenewswire.com/news-relea…

Congratulations to our client @bomboradata on being named “Marketing Insights Platform of the Year” in the 2026 @MarTech_Awards. prnewswire.com/news-releases…

What are advertisers really buying when they pay for “premium” streaming inventory? Read the full article here: forbes.com/councils/forbesbu…

Join AMASS Brands Group (@Nasdaq:$AMSS) for a Live Investor Fireside Chat on Wednesday, July 29th Date: Wednesday, July 29, 2026 Time: 1:00 PM ET | 10:00 AM PT To register: us02web.zoom.us/webinar/regi… Questions for the live Q&A can be submitted in advance to [email protected]

A powerful CBS News story highlights the human impact behind the work of our client RenovoRx. Read the full story by Kerry Breen on @CBSNews: cbsnews.com/news/pancreatic-… #RenovoRx #PancreaticCancer #ClinicalTrials #CancerResearch #HealthcareInnovation